Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Valneva SE
  6. News
  7. Summary
    VLA   FR0004056851

VALNEVA SE

(VLA)
  Report
Real-time Euronext Paris  -  09:44:15 2023-02-07 am EST
6.316 EUR   -2.11%
01/03Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical Study for its Inactivated COVID-19 Vaccine, VLA2001
CI
01/01Valneva's COVID-19 Booster Shot Shows Only Marginally Higher Neutralizing Antibody Response
MT
2022Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EMA: EMA PUBLISHED UPDATED INFORMATION ON COVID-19 VACCINE VALNE…

12/05/2022 | 10:12am EST

EMA: EMA PUBLISHED UPDATED INFORMATION ON COVID-19 VACCINE VALNEVA, WITH AN INCREASE IN ITS APPROVED SHELF LIFE: 05/12/2022


ę Reuters 2022
All news about VALNEVA SE
01/03Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical S..
CI
01/01Valneva's COVID-19 Booster Shot Shows Only Marginally Higher Neutralizing Antibody Resp..
MT
2022Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
GL
2022Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
AQ
2022Certain Stock Options of Valneva SE are subject to a Lock-Up Agreement Ending on 29-DEC..
CI
2022Certain Equity Warrants of Valneva SE are subject to a Lock-Up Agreement Ending on 29-D..
CI
2022Certain Ordinary Shares of Valneva SE are subject to a Lock-Up Agreement Ending on 29-D..
CI
2022Sector Update: Health Care Stocks Mixed Premarket Friday
MT
2022Fresh Inflation Data Eyed as Exchange-Traded Funds, Equity Futures Edge Higher Premarke..
MT
2022Valneva Says it Completed Rolling US Regulatory Submission for One-Shot Chikungunya Vac..
MT
More news
Analyst Recommendations on VALNEVA SE
More recommendations
Financials
Sales 2022 339 M 364 M 364 M
Net income 2022 -72,5 M -77,8 M -77,8 M
Net cash 2022 254 M 272 M 272 M
P/E ratio 2022 -11,9x
Yield 2022 -
Capitalization 893 M 958 M 958 M
EV / Sales 2022 1,88x
EV / Sales 2023 3,59x
Nbr of Employees 762
Free-Float 84,2%
Chart VALNEVA SE
Duration : Period :
Valneva SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 6,45 €
Average target price 10,60 €
Spread / Average Target 64,3%
EPS Revisions
Managers and Directors
Thomas Lingelbach President & Chief Executive Officer
Peter Buhler Chief Financial Officer
FrÚdÚric Grimaud Chairman-Supervisory Board
Michael M÷hlen Vice President-Technical Development
Andreas Meinke VP-Preclinical & Translational Research
Sector and Competitors
1st jan.Capi. (M$)
VALNEVA SE3.66%958
MODERNA, INC.-5.21%65 414
LONZA GROUP AG22.89%44 540
IQVIA HOLDINGS INC.13.38%43 149
ALNYLAM PHARMACEUTICALS, INC.-1.80%27 576
SEAGEN INC.5.83%25 250